Tapinarof Cream 1% Once Daily: Consistent Efficacy Across All Body Regions, Including Head And Neck, In Adults And Children Down 2 Years Of Age With Atopic Dermatitis

Document Type

Conference Proceeding

Publication Date

2-1-2025

Publication Title

J Allergy Clin Immunol

Abstract

Rationale: In the ADORING 1 and 2 phase 3 trials, tapinarof cream 1% (VTAMA®, Dermavant Sciences, Inc.) once daily (QD) demonstrated significant efficacy and was well tolerated in patients with atopic dermatitis (AD) down to age 2 years. Efficacy and tolerability of topicals may vary by body region, particularly sensitive areas including the face/neck. We present Eczema Area and Severity Index (EASI) scores by body region. Methods: 813 patients were randomized to tapinarof or vehicle QD for 8 weeks. EASI, a composite score of 0–72, measures AD severity and extent across four regions: head/neck, trunk, upper extremities, and lower extremities. Results: Mean baseline EASI scores were 12.2–13.5 (standard deviation 4.7–5.6), indicating moderate-to-severe AD. Achievement of ≥ 75% improvement in EASI at Week 8 (tapinarof versus vehicle) was 55.8% vs 22.9% and 59.1% vs 21.2% (both P < 0.0001) in ADORING 1 and 2. At Week 8, least squares (LS) mean overall EASI score improvements from baseline were –8.4 vs –4.1 and –10.1 vs –5.2 (both P < 0.0001). LS mean changes in EASI scores by body region at Week 8 were: head/neck –8.7 vs –4.4 and –8.8 vs –4.7; trunk –5.9 vs –2.6 and –7.2 vs –3.8; upper extremities –12.0 vs –5.2 and –15.0 vs –6.6; and lower extremities –8.6 vs –4.4 and –9.9 vs –5.5 (all P < 0.0001). Tapinarof was well tolerated across sensitive areas, including the face/neck. Conclusions: Tapinarof demonstrated consistent efficacy and was well tolerated across body regions, including the head/neck, supporting its use in treating patients with AD down to age 2 years.

Volume

155

Issue

2

First Page

AB192

Find It @ Sladen

Share

COinS